$IONSIONIS PHARMACEUTICALS INC

📅 Upcoming

🕒 Recent(90d)

News

• Novartis wagers almost $8B on a Chinese biotech’s RNA drugs
  In exchange for a $575 million payment up front, Abogen Biosciences will furnish Novartis with access to its RNA technology, including an option to license its lead program ABO-2203.
  biopharma_dive · 2d ago
• Lawmakers hear mixed opinions on psychedelics credentialing
  As psychedelic drugs inch closer to commercialization, two House lawmakers are charting a path forward for their inevitable rollout and what any potential accompanying legislation could focus on. T…
  endpoints · 3d ago
• RNAi drug specialist ADARx raises $446M IPO
  ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.
  biopharma_dive · 9d ago
• Lilly’s latest China drug deal; Immunovant’s setback in lupus
  Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded a…
  biopharma_dive · 10d ago
• Roche, Ionis RNA drug scores in kidney disease study
  The results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers.
  biopharma_dive · 10d ago
• Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod
  A late-stage test of Roche and Ionis Pharmaceuticals’ sefaxersen showed that the drug reduced protein in the urine, which suggests the RNA-targeting therapy could improve kidney function and delay…
  biospace · 11d ago
• Ionis-Otsuka offer 'groundbreaking' improvement in function and survival for genetic type of ALS
  Ulefnersen, an RNA-targeted therapy being developed by Ionis Pharmaceuticals and Otsuka Pharmaceutical, improved measurements of functional impairment and survival in patients with a rare, genetic…
  biospace · 11d ago
• Roche’s phase 3 win tees up fight with Novartis for blockbuster kidney disease market
  Roche has reported a phase 3 win for sefaxersen in kidney disease, teeing up talks with regulators about the path to approval for the Ionis-partnered, would-be blockbuster candidate.
  fiercebiotech · 11d ago
• Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint
  A phase 3 study of Otsuka and Ionis Pharmaceuticals’ amyotrophic lateral sclerosis drug candidate has hit its primary endpoint, positioning the partners to talk to regulators about expedited approv…
  fiercebiotech · 12d ago
• Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing
  Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course and choosing to offload its lead programs.
  biopharma_dive · 19d ago